Moderna Gets EMA Rolling Review for COVID-19 Vaccine

The European Medicines Agency has begun a rolling review of Moderna’s promising vaccine candidate, mRNA-1273, which demonstrated 94.5 percent efficacy in early results from a phase 3 trial.

Based on the interim data, the messenger RNA-based vaccine appears to have greater efficacy than the Pfizer/BioNTech vaccine, BNT162b2, and it does not need to be stored at a super-cold temperature.

Moderna CEO Stéphane Bancel said the company is scaling up global manufacturing with Lonza of Switzerland, and ROVI of Spain to “be able to deliver approximately 500 million doses per year [or] possibly up to 1 billion doses per year, beginning in 2021.”